Uterine Fibroids Market Analysis, Size, Share & Growth Forecast 2026–2034

Elagolix Oriahnn ELARIS UF 68.5 and 76.5 Percent Heavy Menstrual Bleeding Responder Rate Versus 8.7 and 10.1 Percent Placebo Has Established the Oral GnRH Antagonist Plus Oestradiol Plus Norethindrone Combination as the Non-Surgical Medical Treatment for Symptomatic Fibroid Heavy Bleeding.AbbVie's relugolix-estradiol-norethindrone Oriahnn demonstrated 68.5% response for heavy menstrual bleeding in LIBERTY 1 and LIBERTY 2, achieving the primary endpoint with preservation of bone mineral density through hormonal add-back and allowing indefinite therapy duration that is not achievable with leuprolide depot. The once-daily oral pill administration avoids the monthly injection required for leuprolide, and the elimination of the GnRH agonist flare response enables immediate oestrogen suppression that prevents the initial 2-4 weeks of heavy bleeding that patients experience when initiating leuprolide. The 12-month LIBERTY extension data confirms durability of heavy menstrual bleeding control without progressive bone mineral density loss with continued add-back adherence, establishing the safety basis for long-term medical management of fibroids in women who are not surgical candidates or who wish to defer myomectomy.

Uterine Artery Embolisation 85 to 90 Percent Symptom Improvement at 1 Year With Uterus Preservation Has Established UAE as the Minimally Invasive Alternative to Hysterectomy and Myomectomy for the Woman Who Wishes to Retain the Uterus and Avoid the Surgical Risks.Insightec's ExAblate Sonalleve system delivers transcutaneous focused ultrasound under MR guidance to achieve thermal ablation of fibroid tissue without incision, anaesthesia, or recovery time beyond the same-day outpatient procedure session of 2-4 hours, and 3-year follow-up from TRUST demonstrates symptom scores and fibroid volume maintained below pre-treatment levels in approximately 60% of treated patients. The reintervention rate of approximately 30% at 3 years for MRgFUS is higher than surgical myomectomy but substantially lower than UAE at equivalent follow-up, positioning MRgFUS as a reasonable trade-off between invasiveness and long-term durability for women who strongly prefer non-surgical management. MRgFUS reimbursement coverage has expanded from the initial Medicare coverage to commercial payer coverage across approximately 60% of US insured patients, and the elimination of hospital admission cost by same-day discharge positions MRgFUS as cost-competitive with inpatient myomectomy in total care episode cost analyses.

MRI-Guided Focused Ultrasound ExAblate 40 to 65 Percent Fibroid Volume Reduction From Non-Invasive Transcutaneous Ultrasound Heating and Coagulation Necrosis Has Provided the Outpatient Non-Incisional Fibroid Ablation That Neither Pharmaceutical Nor Surgical Approaches Offer.Gedeon Richter's linzagolix Yselty demonstrated dose-dependent uterine fibroid symptom improvement in PRIMROSE 1 and 2, with the 100 mg dose approved without add-back for short-term use and the 200 mg dose requiring hormonal add-back for longer-term management, providing dosing flexibility that allows individual tailoring of oestrogen suppression depth to symptom severity. The availability of both add-back and non-add-back linzagolix dosing addresses the clinical scenario where some women have contraindications to progestogen add-back, enabling 100 mg use without hormonal supplement in these patients at the cost of incomplete bone mineral density protection that limits duration. European approval of linzagolix and US New Drug Application filing establishes Gedeon Richter as the third GnRH antagonist competitor in the uterine fibroid and endometriosis medical management market alongside AbbVie Oriahnn/Myfembree and elagolix Orilissa.

For related market intelligence, see the Endometriosis Market.